Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction.
Saved in:
| Title: | Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. |
|---|---|
| Authors: | England E; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Rees DG; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Scott IC; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Carmen S; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Chan DTY; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Chaillan Huntington CE; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Houslay KF; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Erngren T; Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Penney M; Early Oncology DMPK, Oncology R&D, AstraZeneca, Cambridge, UK., Majithiya JB; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Rapley L; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Sims DA; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Hollins C; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Hinchy EC; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Strain MD; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Kemp BP; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Corkill DJ; Bioscience In Vivo, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., May RD; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Vousden KA; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Butler RJ; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Mustelin T; Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, USA., Vaughan TJ; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Lowe DC; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Colley C; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Cohen ES; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. suzanne.cohen@astrazeneca.com. |
| Source: | Scientific reports [Sci Rep] 2023 Jun 17; Vol. 13 (1), pp. 9825. Date of Electronic Publication: 2023 Jun 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 37330528 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22England+E%22">England E</searchLink>; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Rees+DG%22">Rees DG</searchLink>; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Scott+IC%22">Scott IC</searchLink>; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Carmen+S%22">Carmen S</searchLink>; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Chan+DTY%22">Chan DTY</searchLink>; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Chaillan+Huntington+CE%22">Chaillan Huntington CE</searchLink>; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Houslay+KF%22">Houslay KF</searchLink>; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Erngren+T%22">Erngren T</searchLink>; Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Penney+M%22">Penney M</searchLink>; Early Oncology DMPK, Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Majithiya+JB%22">Majithiya JB</searchLink>; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Rapley+L%22">Rapley L</searchLink>; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Sims+DA%22">Sims DA</searchLink>; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Hollins+C%22">Hollins C</searchLink>; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Hinchy+EC%22">Hinchy EC</searchLink>; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Strain+MD%22">Strain MD</searchLink>; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Kemp+BP%22">Kemp BP</searchLink>; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Corkill+DJ%22">Corkill DJ</searchLink>; Bioscience In Vivo, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22May+RD%22">May RD</searchLink>; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Vousden+KA%22">Vousden KA</searchLink>; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Butler+RJ%22">Butler RJ</searchLink>; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Mustelin+T%22">Mustelin T</searchLink>; Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Vaughan+TJ%22">Vaughan TJ</searchLink>; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Lowe+DC%22">Lowe DC</searchLink>; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Colley+C%22">Colley C</searchLink>; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Cohen+ES%22">Cohen ES</searchLink>; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. suzanne.cohen@astrazeneca.com. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101563288%22">Scientific reports</searchLink> [Sci Rep] 2023 Jun 17; Vol. 13 (1), pp. 9825. <i>Date of Electronic Publication: </i>2023 Jun 17. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101563288 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2045-2322 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220452322%22">20452322 </searchLink><i>NLM ISO Abbreviation: </i>Sci Rep <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37330528 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41598-023-36642-y Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 9825 Titles: – TitleFull: Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: England E – PersonEntity: Name: NameFull: Rees DG – PersonEntity: Name: NameFull: Scott IC – PersonEntity: Name: NameFull: Carmen S – PersonEntity: Name: NameFull: Chan DTY – PersonEntity: Name: NameFull: Chaillan Huntington CE – PersonEntity: Name: NameFull: Houslay KF – PersonEntity: Name: NameFull: Erngren T – PersonEntity: Name: NameFull: Penney M – PersonEntity: Name: NameFull: Majithiya JB – PersonEntity: Name: NameFull: Rapley L – PersonEntity: Name: NameFull: Sims DA – PersonEntity: Name: NameFull: Hollins C – PersonEntity: Name: NameFull: Hinchy EC – PersonEntity: Name: NameFull: Strain MD – PersonEntity: Name: NameFull: Kemp BP – PersonEntity: Name: NameFull: Corkill DJ – PersonEntity: Name: NameFull: May RD – PersonEntity: Name: NameFull: Vousden KA – PersonEntity: Name: NameFull: Butler RJ – PersonEntity: Name: NameFull: Mustelin T – PersonEntity: Name: NameFull: Vaughan TJ – PersonEntity: Name: NameFull: Lowe DC – PersonEntity: Name: NameFull: Colley C – PersonEntity: Name: NameFull: Cohen ES IsPartOfRelationships: – BibEntity: Dates: – D: 17 M: 06 Text: 2023 Jun 17 Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 2045-2322 Numbering: – Type: volume Value: 13 – Type: issue Value: 1 Titles: – TitleFull: Scientific reports Type: main |
| ResultId | 1 |
